These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10829442)

  • 1. [Prostatic benign hypertrophy: review of effectiveness, tolerance, and impact on quality of life of prolonged treatment with alfuzosin].
    Vela Navarrete R; Gabriel R; Barajas R; Ausín I
    Actas Urol Esp; 2000 Feb; 24(2):120-30. PubMed ID: 10829442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
    McKeage K; Plosker GL
    Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Stalla-Bourdillon A; Attali P
    Br J Urol; 1994 Nov; 74(5):579-84. PubMed ID: 7530121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
    Lukacs B; Leplège A; Thibault P; Jardin A
    Urology; 1996 Nov; 48(5):731-40. PubMed ID: 8911517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: clinical evaluation of impact on patient's quality of life. The Italian Alfuzosin Cooperative Group.
    Eur Urol; 1995; 27(2):128-34. PubMed ID: 7538083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
    Lukacs B; Grange JC; Comet D
    Urology; 2000 Apr; 55(4):540-6. PubMed ID: 10736498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, efficacy and impact on Patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. The Italian Alfuzosin Co-Operative Group.
    Eur Urol; 2000 Jun; 37(6):680-6. PubMed ID: 10828668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3,095 Spanish patients evaluated during general practice.
    Sánchez-Chapado M; Guil M; Alfaro V; Badiella L; Fernández-Hernando N
    Eur Urol; 2000 Apr; 37(4):421-7. PubMed ID: 10765072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group].
    Fourcade RO
    Prog Urol; 2000 Apr; 10(2):246-53. PubMed ID: 10857142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
    MacDonald R; Wilt TJ
    Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
    Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
    Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
    van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
    Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia.
    Grasso M; Montesano A; Buonaguidi A; Castelli M; Lania C; Rigatti P; Rocco F; Cesana BM; Borghi C
    Arch Esp Urol; 1995; 48(1):97-103. PubMed ID: 7537488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
    Lee M
    Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
    McVary KT
    J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia.
    Kirby RS
    Eur Urol; 1998; 33 Suppl 2():19-27. PubMed ID: 9556192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin.
    Saad F; Nickel JC; Valiquette L; Casey R; Kuzmarov I; Elhilali M;
    Can J Urol; 2005 Aug; 12(4):2745-54. PubMed ID: 16197598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy.
    Lukacs B; Blondin P; MacCarthy C; Du Boys B; Grippon P; Lassale C
    Eur Urol; 1996; 29(1):29-35. PubMed ID: 8821687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of alfuzosin on quality of life in benign prostatic hyperplasia patients: preliminary results. Italian Alfuzosin Co-Operative Group.
    Martelli A; Pacifico P; Casadei G
    Eur Urol; 1993; 24 Suppl 1():28-33. PubMed ID: 7687556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.